Kaleida Capital is a San Diego-based venture capital firm founded in 2022 and dedicated specifically to neurotechnology and the future of computation. It focuses on seed and Series A investment in brain health and neuroengineering companies. Compared with broader healthcare investors, Kaleida stands out for being purpose-built around the neurotech thesis.

Its investment interests span AI, diagnostics, biosensors, neuroimaging, neurostimulation, and drug discovery platforms tied to brain health. The firm’s thesis is rooted in the convergence of neuroscience, data, and hardware engineering. This makes it especially relevant to companies that sit at the boundary between neurobiology, computation, and device innovation.

Kaleida appears to be primarily US-focused. For neurotech founders, it is one of the more obvious specialist funds to track because its mandate is explicitly centered on brain health technologies rather than broader healthtech. It is most relevant for early-stage companies seeking a thesis-aligned neurotech investor rather than a generalist healthcare fund.